126 related articles for article (PubMed ID: 9225218)
1. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
Kim DI; Kambayashi J; Shibuya T; Sakon M; Kawasaki T
J Atheroscler Thromb; 1996; 2(2):110-6. PubMed ID: 9225218
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
3. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
[TBL] [Abstract][Full Text] [Related]
4. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
[TBL] [Abstract][Full Text] [Related]
5. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Hara T; Yokoyama A; Morishima Y; Kunitada S
Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
[TBL] [Abstract][Full Text] [Related]
6. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
[TBL] [Abstract][Full Text] [Related]
7. A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.
Kaiser B; Paintz M; Scholz O; Kunitada S; Fareed J
Thromb Res; 2000 Apr; 98(2):175-85. PubMed ID: 10713319
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of early thrombus formation in experimental vein graft.
Itoh T; Kambayashi J; Tsujinaka T; Sakon M; Ohshiro T; Mori T
Thromb Res; 1989 Feb; 53(4):357-65. PubMed ID: 2522689
[TBL] [Abstract][Full Text] [Related]
9. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
10. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
Rezaie AR
Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Gerbutavicius R; Iqbal O; Messmore HL; Wehrmacher WH; Hoppensteadt DA; Gerbutaviciene R; Griniute R; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):317-23. PubMed ID: 14653441
[TBL] [Abstract][Full Text] [Related]
12. DX-9065a, a direct inhibitor of factor Xa.
Kaiser B
Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
[TBL] [Abstract][Full Text] [Related]
13. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Yamashita T; Tsuji T; Matsuoka A; Giddings JC; Yamamoto J
Thromb Res; 1997 Jan; 85(1):45-51. PubMed ID: 8983124
[TBL] [Abstract][Full Text] [Related]
14. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.
Ieko M; Tarumi T; Takeda M; Naito S; Nakabayashi T; Koike T
J Thromb Haemost; 2004 Apr; 2(4):612-8. PubMed ID: 15102016
[TBL] [Abstract][Full Text] [Related]
15. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
Yamaguchi Y; Okabe K; Liang J; Matsumura F; Ohshiro H; Ishihara K; Matsuda T; Takeya M; Kuratsu JI; Mori K; Yamada S; Ogawa M
Dig Dis Sci; 1999 Dec; 44(12):2568-76. PubMed ID: 10630515
[TBL] [Abstract][Full Text] [Related]
16. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Chino D; Fujita Y; Ishii K; Nakayama K
J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
[TBL] [Abstract][Full Text] [Related]
17. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
[TBL] [Abstract][Full Text] [Related]
18. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation.
Nagashima H
J Biol Chem; 2002 Dec; 277(52):50439-44. PubMed ID: 12496240
[TBL] [Abstract][Full Text] [Related]
19. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
Shimbo D; Osende J; Chen J; Robbins J; Shimoto Y; Kunitada S; Fuster V; Badimon JJ
Thromb Haemost; 2002 Nov; 88(5):733-8. PubMed ID: 12428086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
